8 Jul 2026
Board Member Thomas Lehrich will represent AMEND USA as a delegate at the International Neuroendocrine Cancer Alliance (INCA) Conference, to be held on September 6 in Sofia, Bulgaria
AMEND USA announces Board Member Thomas Lehrich will represent AMEND USA and North America as a delegate at the International Neuroendocrine Cancer Alliance (INCA) Conference, to be held on September 6 in Sofia, Bulgaria.As part of this international gathering, Lehrich will also serve as a speaker, joining patient advocates, researchers, clinicians, and policymakers to discuss advancements in neuroendocrine cancer awareness, patient advocacy, research, and international collaboration.Thomas Lehrich’s participation amplifies AMEND USA’s commitment to strengthening international partnerships, advancing patient advocacy, and supporting innovative approaches that improve healthcare outcomes worldwide.
“Representing AMEND USA and joining as a North American delegate at this international conference will continue to improve awareness, encourage collaboration, and help advance better care and research for patients affected by neuroendocrine cancers,” said Lehrich. About the International Neuroendocrine Cancer Alliance (INCA)The International Neuroendocrine Cancer Alliance (INCA) is the global voice supporting patients living with neuroendocrine tumors (NETs) and genetic syndromes (GenNETs). INCA’s mission is to create a unified global platform that brings together patients, healthcare professionals, researchers, and advocacy organizations to improve awareness, promote access to the highest standards of care, support groundbreaking research, and ensure meaningful patient involvement in the development of new treatments.About AMEND USAAMEND USA remains dedicated to empowering patients, supporting education, and building partnerships that improve outcomes and quality of life for those we serve.